-
Mashup Score: 9African Visitor Training Program - Hematology.org - 27 day(s) ago
African Visitor Training Program
Source: www.hematology.orgCategories: General Medicine NewsTweet
-
Mashup Score: 0Black History Month: Sickle cell disease research underway at Yale - 5 month(s) ago
News 8 is once again honoring Black history by looking at health care and the racial disparities many report facing.
Source: www.wtnh.comCategories: General Medicine News, PediatricsTweet-
“It affects every organ in your body,” @cececalhounMD said. “Most notably, we think about debilitating pain, but #SickleCell can affect the brain, eyes, lungs, and every part of the body.” https://t.co/JKq5Yhg9P6
-
-
Mashup Score: 3ASH sickle cell disease research priorities address pain, organ dysfunction, drug development - 7 month(s) ago
American Society of Hematology has issued new sickle cell disease research priorities, highlighting seven key focus areas for maximum impact and benefit to patients.The priorities will serve as a roadmap for promoting sickle cell disease research, educating providers and enhancing standards of care over the next 5 years.
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
The @ASH_hematology has issued new sickle cell disease research priorities — highlighting 7 key focus areas — which will serve as a roadmap for promoting research, educating providers and enhancing standards of care over the next 5 years. #SickleCell https://t.co/0bGRvN4C0t
-
-
Mashup Score: 17The Hematologist | Haploidentical Stem Cell Transplantation Is an Acceptable Transformative Therapy for Young Adults With Sickle Cell Disease - 7 month(s) ago
In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina Chapel Hill, talks with Adetola Kassim, MD, a professor of medicine …
Source: thehematologist.transistor.fmCategories: General Medicine News, Oncologists1Tweet-
New podcast! Join The Hematologist contributing editor Samuel Wilson, MD, and Adetola Kassim, MD, for a discussion about haploidentical stem cell transplantation for young adults with #sicklecell disease. 🎧https://t.co/uMeRXp8Doi https://t.co/VwAjwVBBPN
-
-
Mashup Score: 7
A patient with #sicklecell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
A patient with #sicklecell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics. https://t.co/df9RviBEtu
-
-
Mashup Score: 3‘Discouraging’ results show stroke incidence rising among people with sickle cell disease - 9 month(s) ago
Stroke rates among individuals with sickle cell disease have increased steadily over the last 25 years despite guidelines aimed at prevention, according to results of a retrospective study.Incidence of cerebrovascular events rose significantly with age, with an approximate 13-fold increase of intracranial hemorrhage among people aged 20 to 60 years.
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
Healio spoke with a @PittTweet assistant professor about data showing that stroke rates among individuals with sickle cell disease have increased steadily over the last 25 years despite guidelines aimed at prevention. #SickleCell https://t.co/cuwAXKyS3V
-
-
Mashup Score: 7The Global Fund should extend its mandate to include universal access to hydroxyurea - 9 month(s) ago
Sickle cell disease was recognised as a global public health concern in 2008.1 The 63rd UN General Assembly adopted a resolution that urged member states and UN agencies, funds, programmes, international institutions, and development partners to raise awareness of sickle cell disease on June 19 each year, and to support health systems and delivery of primary care to improve management of sickle cell disease. As the world has commemorated this day since the UN resolution 16 years ago, we urge that sickle cell disease be included in the global health agenda.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet-
“For more than 20 years, The Global Fund to Fight AIDS, Tuberculosis and Malaria has been at the forefront of efforts… with remarkable success... We urge [them] to make hydroxyurea universally accessible for #sicklecell disease… in LMICs” New Comment https://t.co/WjGkPq4pQ2
-
-
Mashup Score: 6Consensus statement helps assess patient readiness for gene therapy in sickle cell disease - 9 month(s) ago
Patient readiness will greatly affect the success of gene therapy for sickle cell disease at the individual and collective levels, according to a consensus statement published in JAMA Network Open. The safety, efficacy and acceptance of gene therapy will determine whether the modality truly can transform sickle cell disease treatment, according to the authors. However, historic medical
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
Healio spoke with @stevenhardyphd of @ChildrensNatl about a consensus statement in @JAMANetworkOpen stating that patient readiness will greatly affect the success of gene therapy for sickle cell disease at the individual and collective levels. #sicklecell https://t.co/ndsK6Vkk2q
-
-
Mashup Score: 11Gene therapy for sickle cell disease remains a tough business model — and may never work - 10 month(s) ago
Gene therapy for sickle cell disease remains a tough business model — and may never work, @adamfeuerstein writes.
Source: www.statnews.comCategories: General Medicine News, General NewsTweet-
The financial restructuring at Bluebird Bio is another reminder that gene therapy for #sicklecell disease remains a tough business model — and may never work, writes @adamfeuerstein. Read: https://t.co/QPDQqjGaZp https://t.co/9VyTTek8s3
-
-
Mashup Score: 5Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets | Pfizer - 10 month(s) ago
Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer’s decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment. Pfizer has notified regulatory authorities about these findings and its decision to voluntarily withdraw OXBRYTA from the market and discontinue distribution and clinical studies while further reviewing the available data and investigating the findings. “The safety and well-being of patients is of the utmost importance to Pfizer, and we believe this action is in the best interest of
Source: www.pfizer.comCategories: General Medicine News, Hem/OncsTweet-
RT @nascc_org: https://t.co/yggi6AqcF4. Attention #SickleCell we need to be careful and WEAN people off Oxbryta and not just stop it. Let u…
-
Are you a hematologist, scientist, or a laboratory staff member working in Africa? Apply for the African Visitor Training Program (AVTP) for the opportunity to receive 12 weeks of training in #SickleCell Disease diagnosis and management. 🔗 https://t.co/mIDGrAansL? https://t.co/zEhaeXX5kg